Department of Molecular Biology, ICMR-National Institute for Research in Environmental Health, Bhopal, India.
Department of Biotechnology, All India Institute of Medical Sciences, New Delhi, India.
Drug Discov Today. 2022 Aug;27(8):2121-2136. doi: 10.1016/j.drudis.2022.04.016. Epub 2022 Apr 20.
Surface-enhanced Raman scattering (SERS) has emerged as one of the most promising platforms for various biosensing applications. These sensing systems encompass the advantages of specificity, ultra-high sensitivity, stability, low cost, repeatability, and easy-to-use methods. Moreover, their ability to offer a molecular fingerprint and identify the target analyte at low levels make SERS a promising technique for detecting circulating cancer biomarkers with greater sensitivity and reliability. Among the various circulating biomolecules, oncomiRs are emerging as prominent biomarkers for the early screening of breast cancers (BCs). In this review, we provide a comprehensive understanding of different SERS-based biosensors and their application to identify BC-specific oncomiRs. We also discuss different SERS-based sensing strategies, nano-analytical frameworks, and challenges to be addressed for effective clinical translation.
表面增强拉曼散射（SERS）已经成为各种生物传感应用中最有前途的平台之一。这些传感系统具有特异性、超高灵敏度、稳定性、低成本、可重复性和易于使用的方法等优点。此外，SERS 能够提供分子指纹并以较低的水平识别目标分析物，这使得 SERS 成为一种很有前途的技术，可以更灵敏、更可靠地检测循环肿瘤生物标志物。在各种循环生物分子中，oncomiRs 作为乳腺癌（BC）早期筛查的显著生物标志物而崭露头角。在这篇综述中，我们全面了解了不同的基于 SERS 的生物传感器及其在识别 BC 特异性 oncomiRs 中的应用。我们还讨论了不同的基于 SERS 的传感策略、纳米分析框架以及为实现有效临床转化而需要解决的挑战。
